ReviewFrontiers in immunology2026
Regulatory T cells in the era of cell and gene therapy: biology, clinical translation, and future prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook.Nanomaterials (Basel, Switzerland) · 2026Review
- Mechanisms of and mitigating strategies for cellular immune responses to CRISPR-associated nucleases in genome editing therapy.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) play a central role in maintaining immune homeostasis. Therefore, owing to their unique immunomodulatory function, their adoptive transfer has been investigated as a novel therapeutic modality. Recent progress in cell manufacturing has allowed the application of Tregs as cell therapy products, and several are being tested in human clinical trials. Furthermore, several clinical trials are aimed at evaluating Treg modulation methods, including cytokine administration, monoclonal antibodies, Treg depletion, and adoptive Treg transfer. Among these, adoptive Treg transfer is a promising cell and gene therapy modality that is potentially beneficial for both genetic and non-genetic diseases, including autoimmunity. To determine the current trends in research on Treg-based therapies, we performed a database search and found that investigational clinical trials have been performed not only for autoimmunity but also for a wide range of diseases. In this mini review, we introduce early benchmarking Treg trials together with recent advances in research on Treg biology shown in non-genetic diseases and not just limited to autoimmunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.